Fragment-based QSAR: perspectives in drug design
- 31 January 2009
- journal article
- review article
- Published by Springer Nature in Molecular Diversity
- Vol. 13 (3), 277-285
- https://doi.org/10.1007/s11030-009-9112-5
Abstract
Drug design is a process driven by innovation and technological breakthroughs involving a combination of advanced experimental and computational methods. A broad variety of medicinal chemistry approaches can be used for the identification of hits, generation of leads, as well as to accelerate the optimization of leads into drug candidates. Quantitative structure–activity relationship (QSAR) methods are among the most important strategies that can be applied for the successful design of small molecule modulators having clinical utility. Hologram QSAR (HQSAR) is a modern 2D fragment-based QSAR method that employs specialized molecular fingerprints. HQSAR can be applied to large data sets of compounds, as well as traditional-size sets, being a versatile tool in drug design. The HQSAR approach has evolved from a classical use in the generation of standard QSAR models for data correlation and prediction into advanced drug design tools for virtual screening and pharmacokinetic property prediction. This paper provides a brief perspective on the evolution and current status of HQSAR, highlighting present challenges and new opportunities in drug design.Keywords
This publication has 62 references indexed in Scilit:
- PK/DB: database for pharmacokinetic properties and predictive in silico ADME modelsBioinformatics, 2008
- Structure-activity relationships for a class of selective inhibitors of the major cysteine protease from Trypanosoma cruziJournal of Enzyme Inhibition and Medicinal Chemistry, 2008
- Developing an Antituberculosis Compounds Database and Data Mining in the Search of a Motif Responsible for the Activity of a Diverse Class of Antituberculosis AgentsJournal of Chemical Information and Modeling, 2005
- CoMFA, HQSAR and molecular docking studies of butitaxel analogues with ?-tubulinJournal of Molecular Modeling, 2004
- Chemical space and biologyNature, 2004
- The role of the medicinal chemist in drug discovery — then and nowNature Reviews Drug Discovery, 2004
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Screening for drug discovery: The leading questionNature, 2002
- High-throughput and virtual screening: core lead discovery technologies move towards integrationDrug Discovery Today, 2000
- High-throughput and virtual screening: core lead discovery technologies move towards integrationDrug Discovery Today, 2000